What is the latest SYNCOMF stock price?
The latest stored price for SYNCOMF is Rs 20.04 as of 2026-09-18.
gimli
SYNCOMF stock AI analysis
SYNCOMF Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
SYNCOM FORMU (I) LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available SYNCOMF price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹20.04
1W return
+4.05%
1M return
+28.71%
3M return
+43.35%
6M return
+67.42%
1Y return
+10.90%
Market cap
₹1,883.76 cr
PE
24.65
PB
4.54
ROE
+20.19%
ROCE
+26.80%
RSI
62.03
Turnover
₹20.56 cr
Why it can matter in screens
- Momentum: SYNCOMF is above 50DMA, above 200DMA; RSI is 62.03.
- Returns: 1D +6.71%, 1W +4.05%, 1M +28.71%, 3M +43.35%, 1Y +10.90%.
- Trend levels: 52W high ₹22.59, 52W low ₹12.79, off high -11.29%.
- Liquidity: latest turnover is ₹20.56 cr; volume vs 20D is +0.71%.
- Valuation/profitability: PE 24.65, PB 4.54, ROE +20.19%, ROCE +26.80%.
- Growth: 3Y sales CAGR +30.02%, 3Y profit CAGR +56.15%.
Quick Answers
Is SYNCOMF above its 50DMA and 200DMA?
SYNCOMF is above 50DMA, above 200DMA. The latest 50DMA is 16.03 and the latest 200DMA is 14.25.
What are SYNCOMF PE, ROE and ROCE?
SYNCOMF has PE 24.65, ROE +20.19%, and ROCE +26.80% in Gimli's latest available snapshot.
How has SYNCOMF performed recently?
SYNCOMF has returned +28.71% over 1 month, +43.35% over 3 months, and +10.90% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 135.41 cr | 36.56 cr | 25.17 cr | 0.27 |
| 2025-12-31 | 115.14 cr | 26.71 cr | 18.91 cr | 0.23 |
| 2025-09-30 | 121.72 cr | 23.65 cr | 16.60 cr | 0.18 |
| 2025-06-30 | 116.90 cr | 21.88 cr | 15.75 cr | 0.21 |
| 2025-03-31 | 148.88 cr | 24.70 cr | 17.69 cr | 0.19 |
| 2024-12-31 | 127.53 cr | 18.77 cr | n/a | nan |
| 2024-09-30 | 102.31 cr | 16.31 cr | n/a | 0.16 |
| 2024-06-30 | 87.26 cr | 11.79 cr | 7.63 cr | 0.11 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 489.17 cr | 108.81 cr | 76.44 cr | 0.81 |
| 2025-03-31 | 465.01 cr | 71.57 cr | 49.43 cr | 0.53 |
| 2024-03-31 | 259.24 cr | 43.03 cr | 25.31 cr | 0.27 |
| 2023-03-31 | 222.49 cr | 34.30 cr | 20.07 cr | 0.22 |
| 2022-03-31 | 231.66 cr | 31.95 cr | 19.79 cr | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 533.85 cr | 5.15 cr | 1.47 cr | 414.99 cr |
| 2025-03-31 | 413.28 cr | 0.66 cr | 4.58 cr | 342.16 cr |
| 2024-03-31 | 404.66 cr | 63.29 cr | 72.49 cr | 288.14 cr |
| 2023-03-31 | 377.83 cr | 0.76 cr | 83.18 cr | 256.01 cr |
| 2022-03-31 | 308.24 cr | 0.22 cr | 0.00 cr | 222.22 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 58.08 cr | 46.41 cr | n/a |
| 2025-03-31 | 23.44 cr | 13.48 cr | n/a |
| 2024-03-31 | -5.96 cr | -14.09 cr | n/a |
| 2023-03-31 | 10.53 cr | -10.11 cr | n/a |
| 2022-03-31 | 16.33 cr | 5.02 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +50.57% | +0.35% | +0.00% | +0.00% | +49.08% | +0.00% |
| 2026-03-31 | +50.57% | +0.21% | +0.00% | +0.00% | +49.21% | +0.00% |
| 2025-12-31 | +50.57% | +0.26% | +0.00% | +0.00% | +49.17% | +0.00% |
| 2025-09-30 | +50.57% | +0.10% | +0.00% | +0.00% | +49.33% | +0.00% |
| 2025-06-30 | +50.57% | +0.41% | +0.00% | +0.00% | +49.02% | +0.00% |
| 2025-03-31 | +50.57% | +0.11% | +0.00% | +0.00% | +49.32% | +0.00% |
| 2024-12-31 | +50.57% | +0.13% | +0.00% | +0.00% | +49.30% | +0.00% |
| 2024-09-30 | +50.57% | +0.10% | +0.00% | +0.00% | +49.33% | +0.00% |
| 2024-06-30 | +50.57% | +0.09% | +0.00% | +0.00% | +49.34% | +0.00% |
| 2024-03-31 | +50.57% | +0.08% | +0.00% | +0.00% | +49.35% | +0.00% |
| 2023-12-31 | +50.57% | +0.00% | +0.00% | +0.00% | +49.43% | +0.00% |
| 2023-09-30 | +50.57% | +0.00% | +0.00% | +0.00% | +49.43% | +0.00% |
| 2023-06-30 | +50.57% | +0.00% | +0.00% | +0.00% | +49.43% | +0.00% |
| 2023-03-31 | +50.57% | +0.00% | +0.00% | +0.00% | +49.43% | +0.00% |
| 2022-12-31 | +50.57% | +0.00% | +0.00% | +0.00% | +49.43% | +0.00% |
| 2022-11-11 | +50.57% | +0.00% | +0.00% | +0.00% | +49.43% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze SYNCOM FORMU (I) with valuation, momentum and industry peers
- Compare SYNCOMF with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare SYNCOMF with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.